Search This Blog

Wednesday, January 26, 2022

Rabobank: IF There Is A Fed Club, Why Can’t They Raise Rates AND Pump Markets?

 By Michael Every of Rabobank

Let’s start with the Fed, and some thoughts that will needle. Stocks slumped in Asia, Europe, and the US session Tuesday - then the US magically rallied again, but not into the green. “The first rule of Fed Club is you don’t talk about Fed Club”; but did someone forget to sell enough bullish puts? Some may not like the idea that central banks are playing with markets, but as Groucho Marx said, “These are my principles. If you don’t like them I have others.” For example, IF there is a Fed Club, why can’t they raise rates AND pump markets? If secretly selling puts holds up stocks, and you can do that AND raise Fed Funds to pretend you are serious about supply-side inflation you can’t control,…then why not?

Similarly, why can’t you raise rates AND do QE? Yes, ‘they run in opposite directions on yields’. But if you want to finance a huge budget deficit while cooling the heels of the rest of the economy, buy freshly issued government bonds, with higher coupons flowing back to the treasury to boot, and raise rates.

On which, we published a note called “The Ukraine Metacrisis” yesterday underlining that:

  • Markets are significantly mispricing the odds of an impactful war happening over Ukraine, with major volatility implied for energy, grains, fertilizer, metals, rates, and FX.
  • The market impact of US sanctions could be extraordinary; at worst, they could bifurcate the globe into complying and non-complying countries - yet a failure to use sanctions would show US powerlessness to prevent Russia moving on Ukraine; and
  • This is a metacrisis that will see an acceleration towards a different globalization in which the US can still thrive, but with huge challenges for many others, including the EU.

Recent developments underline and amplify that message.

In terms of war: more troops and equipment are still arriving from all over east, and west; the US is flagging it may send more than 8,500 soldiers to the EU; more NATO/Quad countries are asking nationals in Ukraine to leave or making lists of them (as the US flags it won’t help you if anything happens); and China’s Global Times has an exclusive – “Dirty trick again! US plots to authorize departure of staff from embassies in China over epidemic ahead of Beijing Olympics”. Over Covid, eh?

In terms of economics and finance: President Biden has stated a Russian invasion would “change the world”; a Russian senator has warned that if Russia is cut off from SWIFT, Europe won’t receive Russian oil, gas, or metals – but that it can work around a SWIFT ban anyway, and expects other countries to join it in that effort; and the White House has stressed that it will redirect global gas supplies from elsewhere to Europe and use Huawei-style global export controls as a primary economic sanctions tool against Russia, cutting it off from US technology, computing, aviation, etc.  

In short, the fattening tail risks are of a tipping point towards a bifurcated global economy – no matter how illogical some of the projected market pricing then is (i.e., supply gluts in some places, shortages in others). It still seems unlikely the present phase of this metacrisis will get us to that endpoint: but it is a large step in that direction, and if it extends to Asia the probabilities will shift.

The same bifurcation of economic ecosystems is already evident in musician Neil Young (who is old enough that Lynyrd Skynyrd asked him musical questions) has demanded his music is removed from Spotify because it also hosts Joe Rogan. As Rolling Stone magazine, which used to lionise 70’s ‘rawk’n’rewl’ excesses but is now deeply political and politically-correct, notes: “Young’s letter was addressed to his manager and a Warner executive. At press time, Spotify hadn’t responded to a request from Rolling Stone asking if they planned to remove Young’s music. It’s still available, but it might be smart to listen to Zuma and Rust Never Sleeps while you still can. They could disappear at any moment.“ And so could lots of other things – because once we start down the road of responding to feeling needled by imposing a “me or them” binary, damage is done. When do they come for Eric Clapton, one asks, as we “Keep on rockin’ in the ‘free’ world.”?

Meanwhile, the IMF (“Keep on rockin’ in the ‘free markets’ world”) just released its latest outlook, which stresses the world economy rests on one dyad: the Fed and Chinese housing. The former is looking tragicomically wrong unless they ‘raise and pump’, say markets; the latter sees Bloomberg report local government vehicles are buying land plots over the heads of struggling developers at above market valuation when that land is owned by the local government - borrowing money to buy assets from themselves to crack down on private developers and yet not the overall economy. Why are we so close to a global bifurcation when we actually have so much in common?!

Of course, this overlooks the inherent risks to markets of the Fed tightening and China loosening (wild swings); which would also run true for the Fed loosening and China tightening (wild swings); and for the Fed and China both tightening (wild crash); or, note well, of the Fed and China both loosening (wild inflation – and even Singapore’s MAS tightened unscheduled yesterday for only the third time in 20 years). Think about that and one starts to see the *logical* appeal of much deeper bifurcation: or of central global planning. But I have probably needled too much today already.

Except I also have to add that we will now get to see more details of the police interrogation of British PM BYO; a looming, critical report into his Conservative ‘Party’; and what will be No. 10 attempts to spin all this as ‘Fifty Shades of Gray’ rather than “I’ll get my coat”. Moreover, in Italy there is still no white smoke as they try to elect a new president, with potentially major implications for markets. Throw in a new, clashing German leadership and an election in France in months, along with deeply unpopular US leadership, and it’s hardly the perfect backdrop for the kind of ‘thread the needle’ geopolitical decisions that will have to be made to avoid causing too much damage.

https://www.zerohedge.com/markets/rabobank-if-there-fed-club-why-cant-they-raise-rates-and-pump-markets

Teen charged with murder in 12-year-old's fatal overdose

 A California teen has been arrested and charged with murder, accused of selling a fentanyl-laced pill to a 12-year-old child.

The Santa Clara County District Attorney Office (SCCDAO) said San Jose Police Department officers arrested the teen on Tuesday. 

Authorities found in the suspect's Google Photos page screenshots of public service warnings over fentanyl overdoses, according to the statement. 

The 12-year-old girl was with two friends when she purchased the “M-30” pill from the 16-year-old suspect on Nov. 14, 2020. 

Prosecutors said her friends then recorded a video of her lining up the crushed pill for ingestion. 

After snorting the fentanyl-laced pill, the child passed out and began to snore, a sign of a fentanyl overdose, according to the statement. 

According to the Centers for Disease Control and Prevention (CDC), fentanyl is a synthetic drug that can be 50 times stronger than heroin and 100 times stronger than morphine. The SCCDAO said that illicitly-made fentanyl is commonly made to resemble prescription drugs. 

The girl was pronounced dead by medical officials after her friends brought her to the Regional Medical Center in San Jose, Calif. 

This is the second time the SCCDAO has charged a someone with murder after a fatal overdose. A San Jose, Calif., man is also facing a murder charge after selling an opioid that led to a fatal overdose through social media platform Snapchat to an 18-year-old in 2020.

“After thousands of deaths, everyone should know that fentanyl is a deadly poison,” District Attorney Jeff Rosen said in the statement. “Thanks to the San Jose Police Department, the Santa Clara County Specialized Enforcement Team, and our investigators, this child’s tragically short life may help save others.” 

The charged minor is expected to face prison time for the charges against him, the statement noted. 

https://thehill.com/homenews/state-watch/591431-teen-charged-with-murder-in-12-year-olds-fatal-overdose

Disney says it's consulting with 'dwarfism community' after Peter Dinklage knocks 'Snow White' remake

 

  • Actor Peter Dinklage spoke about the upcoming live-action remake of “Snow White and the Seven Dwarfs” on a podcast Monday.
  • Dinklage discussed what he perceives as contradictory standards for updating the 85-year-old film for today in its portrayal of dwarfs.
  • Disney responded, stating it was consulting the “dwarfism community” to avoid stereotypes.

Disney said it’s consulting with the “dwarfism community” on its upcoming live-action remake of “Snow White” following criticism from actor Peter Dinklage. 

“To avoid reinforcing stereotypes from the original animated film, we are taking a different approach with these seven characters and have been consulting with members of the dwarfism community,” a Disney spokesperson told The Hollywood Reporter on Tuesday. “We look forward to sharing more as the film heads into production after a lengthy development period.” 

Dinklage had commented on the proposed remake while appearing on Marc Maron's "WTF" podcast on Monday, citing what he perceives as contradictory standards for updating the 85-year-old film for modern times. 

"No offense to anybody, I was a little taken aback when they were very proud to cast a Latina actress as Snow White. You're still telling the story of 'Snow White and the Seven Dwarfs.' Take a step back and look at what you're doing there. It makes no sense to me," Dinklage said.  

The live-action remake is set to star “West Side Story” actor Rachel Zegler as Snow White and “Wonder Woman” actor Gal Gadot as the Evil Queen.  

"You're progressive in one way and you're still making that f---ing backwards story about seven dwarfs living in a cave together, what the f--- are you doing man?” Dinklage added. “Have I done nothing to advance the cause from my soapbox? I guess I'm not loud enough."  

“All love and respect to the actress and the people who thought they were doing the right thing, but I’m just saying, what are you doing?” the actor added. “And if you tell the story of Snow White with the most f------ up, cool, progressive spin on it, let’s do it. All in. But I don’t know.”  

https://thehill.com/changing-america/enrichment/arts-culture/591439-disney-says-its-consulting-with-dwarfism-community

Could just 10 minutes of daily exercise extend life?

 New research suggests just 10 minutes of daily exercise for those above the age of 40 could extend life expectancy.

In a study published by the JAMA Internal Medicine journal on Monday, researchers found 10 minutes of exercise a day could have saved the lives of around 110,000 people aged 40 to 85 per year.

An increase to 20 or 30 minutes of exercise a day could save even more lives, with the authors saying this is the first study they know of using accelerometer-based measurements to estimate the number of lives that could be saved through physical activity. 

They used data from the National Health and Nutrition Examination Survey to study the activity levels of those in their age range and when they died through the end of 2015. 

"We know exercise is good for us. This study provides additional evidence of the benefits at the population level: if all adults in the United States (over age 40) were to exercise just a bit more each day, a large number of deaths could be prevented each year," epidemiologist Pedro Saint-Maurice, the study's first author, told CNN.

"We have reported previously that even a little bit of exercise can result in health benefits," Saint-Maurice said. "This study doesn't focus on the benefits for individuals, but rather at the level of the population. We can make our nation healthier by encouraging everyone to add an additional 10 minutes of activity or more each day." 

https://thehill.com/policy/healthcare/591438-new-research-suggests-just-10-minutes-of-daily-exercise-could-extend-life

Cyclerion Starts Phase 2a Study in Alzheimer’s Disease with Vascular Pathology

 Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that patient dosing has begun in its Phase 2a study in Alzheimer’s Disease with Vascular Pathology (ADv).

“The need for effective new treatments for Alzheimer’s disease is immense, and, given the aging population demographics and increasing rate of diagnosis, this need will continue to expand. We believe that CY6463 has potential to provide meaningful cognitive benefits and are very pleased to have initiated this important clinical study,” said Andreas Busch, Ph.D., Chief Scientific Officer of Cyclerion. “Our CY6463 ADv development efforts are supported by preclinical data which demonstrate beneficial effects on cognition measures and the neuronal and microglia cellular activity thought to have a central role in the pathology and the cognitive dysfunction experienced by individuals living with ADv. Furthermore, a Phase 1 study in elderly subjects demonstrated an impact on biomarkers relevant to neurodegeneration and cognitive impairment. The ongoing Phase 2a study will focus on a segment of the Alzheimer’s disease population where we believe our therapeutic candidate has the best opportunity to provide a clinical benefit. We expect this trial to deliver a rich dataset that will deepen our understanding of the therapeutic potential of CY6463 and will enable well-informed decisions regarding further development.”

The Phase 2a ADv study (NCT04798989) is a randomized, placebo-controlled study of oral once-daily CY6463 in approximately 30 participants over a twelve-week dosing period. Study participants must have confirmed Alzheimer’s disease pathology as assessed by PET or CSF biomarkers, cardiovascular risk factors, as well as mild-to-moderate subcortical small-vessel disease as assessed by MRI. The study will evaluate safety, tolerability, and pharmacokinetics as well as explore the impact on various disease-relevant pharmacodynamic biomarkers (e.g., EEG, MRI, neuroinflammatory biomarkers) and cognitive performance.

Akili inks $1B SPAC deal to take prescription video game tech public

 Less than two years after scoring its first FDA clearance, Akili Interactive is betting big on its digital therapeutic technology.

The Massachusetts-based company has signed a reverse-merger deal with Social Capital Suvretta Holdings Corp. I—a special purpose acquisition company (SPAC) that completed a $220 million IPO last summer—to make its own public debut. Once the deal is complete, the combined company will operate under the Akili name and trade on the Nasdaq as “AKLI.”

At the close of the transaction, the newly public Akili is expecting to boast a total equity value of about $1 billion. The transaction is forecast to be finalized sometime around the middle of this year.

According to the startup, the SPAC deal will help ramp up the commercial launch of EndeavorRx, Akili’s FDA-cleared and CE marked program designed to improve attention function in children with attention deficit hyperactivity disorder (ADHD).

Plus, the proceeds from the transaction and Akili’s subsequent public debut will help speed up development of its other digital therapeutics to treat symptoms associated with a range of neuropsychiatric diseases including multiple sclerosis, autism, depression and more.

Those proceeds are expected to tally up to $412 million, including a $162 million private investment round from several new and existing backers that Akili is planning to close in the lead-up to the reverse merger.

The bulk of the private round, $100 million, will come from Social Capital, parent company of Akili’s SPAC partner, while the remaining $62 million has already been pledged by a group of investors that includes Averill Strategy, Apeiron Investment Group, Temasek, Polaris Partners, Evidity Health Capital, Jazz Venture Partners, Omidyar Technology Ventures and PureTech Health, which helped establish Akili in 2011.

Akili’s EndeavorRx technology in 2020 became the first prescription video game cleared by the FDA. The system tasks children with ADHD between the ages of eight and 12 with working their way through multiple levels of an interactive game filled with sensory stimuli and motor challenges that have been clinically proven to activate the parts of the brain linked to attention.

Clinical trial results included in the FDA submission showed that playing the game—which relies on an internal algorithm to constantly adapt to fit each player’s needs and abilities—can alleviate ADHD symptoms, with about 50% of parents reporting improvements in their child’s day-to-day symptoms and nearly 60% saying the game improved attention.

Since garnering the groundbreaking FDA nod, Akili has proceeded on a path of rapid growth. Last May, it blew its own previous fundraising tally out of the water, closing a series D funding round worth $110 million. And the following August, it shelled out about a third of that amount to license a new portfolio of attention-improving digital therapeutics from Tali Digital.

https://www.fiercebiotech.com/medtech/akili-inks-1b-spac-deal-to-take-prescription-video-game-tech-public

CytoDyn board ousts CEO after wild year, leaving an albatross of a C-suite job to fill

 CytoDyn President and CEO Nader Pourhassan, Ph.D., is out, and Chief Financial Officer Antonio Migliarese is in, at least for the interim, in the latest twist in one of the wildest tales in biotech.

The embattled company, which has been trying for the past year to prove its therapy leronlimab can work in diseases from cancer to COVID-19 to HIV, unveiled the leadership change Tuesday morning. Pourhassan’s termination is effective Jan. 24, and he has been removed from the board of directors as well. He's been CEO since 2012.

The board will now start searching for a replacement with the candidate ideally “possessing the requisite pharmaceutical industry experience to enhance the company’s efforts to achieve regulatory approval and commercialization of leronlimab.” Migliarese will continue to serve as CFO as he picks up the duties of interim president.

Board Chairman Scott Kelly, M.D., who also serves as chief medical officer, will step down from the board as well to “enhance the board’s independence,” the company said. Tanya Durkee Urbach will take his seat.

“Now is the right time for the next phase of CytoDyn’s evolution, as we focus on continuing the clinical progress of leronlimab and ultimately securing regulatory approval and commercialization,” Kelly said in a statement. “We thank Dr. Pourhassan for his vision and passion for developing leronlimab into a platform molecule with the potential for multiple therapeutic indications.”

There’s a lot to unpack in the CytoDyn story. Leronlimab is a monoclonal antibody that the biotech has tested in a handful of indications. The drug failed a COVID-19 trial last year, despite the company’s insistence that it could treat patients with severe disease. The FDA disagreed, publicly chastising CytoDyn for cherry-picking data to suggest the failed drug was a success.

The public statements also caught the scrutiny of the Department of Justice and the Securities and Exchange Commission (SEC). CytoDyn has been subpoenaed by both agencies for documents related to leronlimab and public statements about its potential use in COVID-19, triple-negative breast cancer and HIV.

After the rare public smackdown, Pourhassan presided over a bizarre press conference in which he begged investors to stop trashing the FDA.

“You can throw all kinds of eggs and tomatoes, whatever you like, at me. I deserve it,” he said. “But please don’t do that to the regulatory agency.”

That’s not all the drama. Last year, the FDA sent over some instructions to help CytoDyn recover an application for leronlimab in HIV after the company accidentally sent in the wrong data sets.

CytoDyn’s investors are a dedicated group that swarm Twitter (and Fierce Biotech’s inboxes) to defend leronlimab at the slightest mention of the treatment’s troubles. One group of investors has even pitched its own solution to get leronlimab across the finish line in cancer.

The incoming CEO will have a tough role to fill. This person will need to help CytoDyn regain credibility and smooth over the mistakes of 2021, and, hopefully, put up some more data to support leronlimab’s approval in one of the indications the company is aiming for.

But there's not a lot of money in the company's coffers to get that done. In a recent report to the SEC (PDF), the company said “our cash reserves are extremely low,” and substantial additional financing would be needed to “satisfy our current payment obligations and to fund our operations.”

“If we fail to raise additional funds on a timely basis, we may be forced to delay, reduce the scope of, or eliminate one or more of our clinical trials or postpone our regulatory submissions and commercialization initiatives, which would adversely affect our business, financial condition, and stock price. If we deplete our cash reserves, we may have no choice but to discontinue our operations and liquidate our assets,” the filing said.

CytoDyn has already missed a payment to Samsung, which provides contract manufacturing services for the company, in the amount of $13.5 million. An additional payment of $22.8 million is due Jan. 31.

And then there’s a dispute with a former contract research organization, which CytoDyn says has caused a delay in filing leronlimab in HIV.

The new chief executive will have to deal with these issues all while presiding over an investor army for a company that has seen a share decline from a high of $7.15 apiece a year ago to just 53 cents in premarket trading Wednesday.

But as the market opened, CytoDyn's shares popped nearly 12% to 58 cents, suggesting the investor community is happy to see a change. 

https://www.fiercebiotech.com/biotech/cytodyn-ousts-ceo-after-a-wild-year-leaving-board-albatross-a-c-suite-job-to-fill